Beam Therapeutics Inc
NASDAQ:BEAM
Beam Therapeutics Inc
Operating Income
Beam Therapeutics Inc
Operating Income Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Operating Income | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Beam Therapeutics Inc
NASDAQ:BEAM
|
Operating Income
-$415.6m
|
CAGR 3-Years
-2%
|
CAGR 5-Years
-41%
|
CAGR 10-Years
N/A
|
|
|
Abbvie Inc
NYSE:ABBV
|
Operating Income
$16.5B
|
CAGR 3-Years
-5%
|
CAGR 5-Years
4%
|
CAGR 10-Years
16%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Operating Income
$10.8B
|
CAGR 3-Years
3%
|
CAGR 5-Years
19%
|
CAGR 10-Years
-3%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Operating Income
$7.3B
|
CAGR 3-Years
-7%
|
CAGR 5-Years
-6%
|
CAGR 10-Years
0%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Operating Income
$4.4B
|
CAGR 3-Years
16%
|
CAGR 5-Years
30%
|
CAGR 10-Years
N/A
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Operating Income
$4.2B
|
CAGR 3-Years
-22%
|
CAGR 5-Years
14%
|
CAGR 10-Years
18%
|
|
Beam Therapeutics Inc
Glance View
Beam Therapeutics Inc. stands at the cutting edge of the biotechnology sector, pioneering the fascinating realm of gene editing through its unique approach known as base editing. Conceived from the intellectual explorations of world-renowned scientists, Beam Therapeutics intertwines science and innovation to redesign the genetic fabric that defines life. Unlike traditional gene-editing techniques that involve breaking the DNA strands, Beam’s base editing is precise and subtle, modifying individual letters of the genetic code without introducing double-stranded breaks. This precision technology has significant implications, offering potential treatments for a spectrum of genetic disorders that have long eluded medical science. The company’s business model is intricately linked to the commercialization of its novel base editing platforms and the development of therapeutic candidates targeting critical genetic diseases. By strategically partnering with pharmaceutical giants, Beam Therapeutics leverages its cutting-edge technology to stimulate revenue streams through collaborations and licensing agreements. Additionally, the company aims to navigate the complex pathways of regulatory approval, advancing its drug candidates from laboratory research through clinical trials towards eventual market rollouts. As such, Beam Therapeutics is not merely focused on scientific discovery but is equally committed to transforming these breakthroughs into viable products that can, one day, redefine the clinical landscape of genetic medicine.
See Also
What is Beam Therapeutics Inc's Operating Income?
Operating Income
-415.6m
USD
Based on the financial report for Dec 31, 2024, Beam Therapeutics Inc's Operating Income amounts to -415.6m USD.
What is Beam Therapeutics Inc's Operating Income growth rate?
Operating Income CAGR 5Y
-41%
Over the last year, the Operating Income growth was -135%. The average annual Operating Income growth rates for Beam Therapeutics Inc have been -2% over the past three years , -41% over the past five years .
You don't have any saved screeners yet